Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Hyperlipidemia Drugs: Global Market Analysis & Forecast Report by Drug Class (2016-2022) - ResearchAndMarkets.com

Research and Markets
Posted on: 02 Nov 18

The "Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, expanding at a CAGR of 2.3% during the forecast period.

Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.

Key Findings

  • Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy
  • Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile
  • PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients
  • Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia
  • There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid
  • AstraZeneca, Merck & Co., Inc., Pfizer, Inc., DAIICHI SANKYO COMPANY, LIMITED, Amgen, Inc., and Sanofi are some of the key players operating in this market
  • Amgen, Inc., Sanofi, and Esperion are expected to have the highest shares in this market by 2022

Companies Profiled

  • AstraZeneca
  • Merck
  • Pfizer
  • Daiichi Sankyo
  • Amgen
  • Sanofi

Topics Covered

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Hyperlipidemia Drugs Market Overview

Chapter 5 Hyperlipidemia Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/hcz8j8/hyperlipidemia?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005450/en/

Business Wire
www.businesswire.com

Last updated on: 02/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.